drugset / Trial / NCT00649532
Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the bioequivalence of Mylan's ondansetron 24 mg tablets to GSK's Zofran® 24 mg tablets following a single, oral 24 mg (1 x 24 mg) dose administered under fasting conditions.
Timeline
- Start
- 2003-07
- Primary completion
- 2003-07
- Completion
- 2003-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ondansetron | Other / unclassified | 24 mg | Oral |
Indications
No indication recorded.